Latest Leadership News

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Shine Justice Ltd reported a modest 2.3% revenue increase to $209.2 million for FY26, alongside a striking 1,578% jump in net profit after tax to $9.6 million. The company declared a fully franked final dividend of 2.5 cents per share, signalling confidence amid ongoing investments in technology and international expansion.

Julian Cook has resigned as an executive director of Winton Land, citing fundamental disagreements with the majority shareholder on board roles and governance, following similar departures by other directors.

Sky Network Television Limited posted a robust FY26 with 9% revenue growth, a 45% dividend increase, and secured major sports rights through 2034, underpinned by the integration of Sky Free.

Synlait Milk anticipates a modest improvement in underlying EBITDA for FY26 but expects a substantial net loss after tax, reflecting ongoing operational challenges and a tough first half.

Air New Zealand reported a $242 million net loss after tax for FY2026, hit by soaring fuel costs linked to the Middle East conflict and persistent engine issues. The airline unveiled a new strategy aiming for operational resilience and targeted growth amid ongoing cost pressures.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Bentley Capital Limited swung back to profitability in FY2026, posting a $255,000 net profit driven mainly by legal settlements and modest investment gains, reversing a prior loss of $878,000.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.